In this episode, David Flores speaks with Matt Zemon, the co-founder of Happy and author of Psychedelic for Everyone. David and Matt open up about personal stories about their childhood, with Matt sharing a beautiful story about connecting with his son Cole.
Similar Posts
Interview With Carlos Tanner
In this episode, Global Trac Solutions, Inc. CEO, David Flores, has the very distinct pleasure of being joined by Carlos Tanner, founder of the Ayahuasca Foundation in Iquitos, Peru.
Field Trip Uplists to Nasdaq | Cybin to NYSE | Mydecine MDMA Patent: Big Week For Psychedelic Stocks
Big Week For Psychedelic Stocks: Field Trip Uplists to Nasdaq, Cybin Uplists to NYSE & Mydecine Files A NEW MDMA Patent!
On July 23, Field Trip Health, (FTRP: TSX), ( FTRPF: OTC), announced that they received conditional approval from The NASDAQ Stock Market to uplist to the Global Select Tier of that market, subject to fulfilling any remaining conditions as required by NASDAQ. The date for the uplisting is still to be confirmed, though we should expect an announcement shortly.
Cybin Inc., (CYBN: NEO), ( CLXPF: OTC), also announced that they received conditional approval to uplist to the NYSE. Like with Field Trip, this uplisting to the NYSE is still conditional on several technicalities, so it is not a 100% done deal yet. Once these procedural steps have been taken, a date will be announced.
In other news, Mydecine, (MYCO: NEO), (MYCOF: OTC), has announced that the company has filed a patent to include MDMA-like molecules. This is exciting, because MDMA to treat PTSD is one of the most exciting applications of psychedelic therapy and the results from the most recent MAPS study looking at MDMA to treat PTSD were groundbreaking.
Links:
FIELD TRIP HEALTH LTD. OBTAINS CONDITIONAL APPROVAL TO LIST ON NASDAQ UNDER THE SYMBOL “FTRP”:
https://thepsychedelicinvestor.com/2021/07/23/field-trip-health-ltd-obtains-conditional-approval-to-list-on-nasdaq-under-the-symbol-ftrp/
CYBIN ANNOUNCES CONDITIONAL LISTING APPROVAL FROM NYSE AMERICAN:
https://thepsychedelicinvestor.com/2021/07/23/cybin-announces-conditional-listing-approval-from-nyse-american/
MYDECINE EXPANDS PORTFOLIO OF NOVEL MOLECULES FILING NEW PATENT FOR MDMA-LIKE COMPOUNDS:
https://thepsychedelicinvestor.com/2021/07/24/mydecine-expands-portfolio-of-novel-molecules-filing-new-patent-for-mdma-like-compounds/
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#FieldTripHealth #Cybin #Mydecine
Interview with James Lanthier, CEO of Mindset Pharma
In our conversation, James goes into detail about Mindset’s new lead drug candidate MSP-1014, when the company expects to take the drug to clinical trials, and why next generation drugs are an important commercial opportunity for anyone looking to invest in the psychedelic sector.
Psychedelic Spotlight Interview with Joshua White
In this episode of the Psychedelic Spotlight podcast, we speak…
More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)
Today we’ll discuss More MindMed Catalysts: MMED MMEDF Stock Opportunity (Plus Jr & Kevin O’Leary comments)
Today’s episode is a short follow up video to our last episode, where we looked at the catalysts for MindMed and MindMed stock in 2021.
We have already covered the NASDAQ uplisting, Clinical trial updates that MindMed will give this year and Conference calls and possible financing deals. But of course, we missed a few of important possible catalysts, as you guys so rightly pointed out.
So in this episode we are briefly going to run through them.
So what else can MindMed and MMED/MMEDF investors expect this year?
1. The imminent launch of the first Psychedelic Medicines ETF, The North American Psychedelics Index (PSYK)
-When will it launch?
-In what manner will it affect MindMed
-And how much it will influence MindMed’s stock price
2. Atai Life Sciences expected IPO how that’ll affect MindMed
– How will the IPO of another big rival will affect MMED/MMEDF?
3. Potential catalyst of Partnerships, Mergers and Acquisitions
-Coming directly from an Interview with JR Rahn and Kevin O’Leary
Unlike the 1st two catalysts we discuss here, as well as a potential Nasdaq uplisting, future partnerships mergers and acquisitions would affect MindMed’s long term value, and their ability to develop, produce and distribute game changing medicines.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media!
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://mindmed.co/news/press-release/mindmed-expands-psychedelic-microdosing-division-adds-groundbreaking-study-evaluating-lsd-microdosing-through-next-gen-digital-clinical-markers/
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #MMED #MMEDF
The Psychedelic Sector has Reached “Escape Velocity” | An interview with Cybin’s CEO (CYBN)
In this episode, James, The Psychedelic Investor, sits down with Doug Drysdale, CEO of Cybin (NYSE: CYBN) for the Psychedelic Spotlight podcast.
In the interview, the two discuss Cybin’s psychedelic medicines portfolio, and where the psychedelic industry is going in the next few years. Can psychedelics heal mental health?
The main topic was attempting to answer the question: can psilocybin heal mental health conditions like depression?
Doug Drysdale spoke on the positive results we have seen in psilocybin for depression clinical trials, such as the Compass Pathways’ psilocybin (comp 360) for treatment-resistant depression phase 2b trial. Despite the apparent benefits of psilocybin, though, Doug Drysdale and Cybin argued that there were 3 core problems with using psilocybin in a therapy setting: the long duration of effect; the onset action period; and the variability of effect.
Cybin has developed a new version of psilocybin, called CYB-003. CYB-003 has a shorter duration, reaches peak effect quicker, and has less variability in effect between individuals. Plus, it keeps all of the therapeutic benefits of psilocybin and its subjective effects.
It is important to note that Cybin’s Cyb-003, their next-generation psilocybin, has only been tested in animals up until this point. They intend to start human clinical trials next year.
James and Doug of Cybin also discussed the other Cybin projects, such as CYB-004, and their development strategy. They also discussed government policy, and whether the psychedelics sector has reaches escape velocity.
In all, this psychedelic medicines conversation was fascinating and showed Cybin’s dedication towards improving mental health conditions, which are abysmal in the United States right now.
Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Cybin #Psilocybin #Psychedelics